Home
Products
Learn
About
Pricing
Log In
ATEC
Asset Logo

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

📙 Holdings

💰 Distributions

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual capital growth

💰

0.77%
Annual distribution yield

Based on the most recent distribution

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

97
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

ATEC.AX was created on 2020-03-04 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 175.82m in AUM and 38 holdings. The investment objective of the Fund is to provide an investment return that aims to track the performance of the S&P/ASX All Technology Index (the Index), before taking into account fees and expenses.

📝 View Factsheet

📈 Performance

Price History

+27.80%

1M

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

📙 Top Holdings

Show more
XERO LTD
11.63%

Updated as of 16 September 2022

Industry Exposure
🤖 Information
55%
📞 Communication
27%
🏭 Industrials
9%
🩺 Health
3%
📙 Other
3%
🛍️ Consumer
1%
🏦 Financials
1%
Country Exposure
🇦🇺 Australia
85%
🇳🇿 New Zealand
12%
🇺🇸 United States of America (the)
2%

💰 Distributions

Payouts

💰 Annual Distribution Yield*

0.77%

💰 Annual Distribution Earnings Per $1,000 invested**

$7.73

💰 Most Recent Distribution Franked Percentage Estimate

71.10%

💰 Average Distribution Franked Percentage Estimate

58.49 %

💰 Distribution reinvestment

Learn more

* Based on the most recent distribution

** Calculated by multiplying the most recent distribution yield by $1,000

Distribution History

1Y

5Y

10Y

Graph

Table

Year
Yearly Distribution Earnings Per Share
Franking Estimate

2025

$0.00

0.00%

2024

$0.00

0.00%

2023

$0.00

0.00%

2022

$0.08

71.10%

2021

$0.67

Infinity%

2020

$0.27

13.55%

2019

$0.00

0.00%

2018

$0.00

0.00%

2017

$0.00

0.00%

2016

$0.00

0.00%

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0.48%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$18.71

💰 Price To Earnings Ratio

29.89

💰 Price To Book Ratio

4.90

💰 Leveraged

No

💰 Inverse

No

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in ATEC

97

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in ATEC

684 days
ATEC investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

16%

50k - 100k

42%

Less than 50k

28%
👶 Age of investors

18 - 25

12%

26 - 34

45%

35 - 90

42%
🙋 Legal gender of investors

Female

44%

Male

56%

Pearlers who invest in ATEC also invest in...

Betashares Nasdaq 100 Etf

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

📊 Share price

$34.01 AUD

NULL US

NULL EX AUSTRALIA

NULL BETA

Find Out More

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

📊 Share price

$90.18 AUD

NULL AUSTRALIA

NULL BETA

ACDC

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

📊 Share price

$100.01 AUD

NULL GLOBAL

NULL OTHER

NULL SMART BETA

NULL THEMATIC

NULL INDEX

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

📊 Share price

$120.79 AUD

NULL AUSTRALIA

NULL BETA

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

📊 Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

Want more shares? Try these...

Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company is headquartered in Melbourne, Victoria and currently employs 12 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

📊 Share price

$0.01 AUD
Compare
Add to watchlist